Douglas Hay

Dr. Douglas W.P. Hay obtained his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland. Douglas is a Pharmaceutical Executive with more than 20 years in Drug Discovery, with particular expertise in respiratory and inflammatory disease therapeutic areas. Douglas joined GSK in 1985, and from 2001-2007 he was Vice President of the Chronic Obstructive Pulmonary Disease (COPD) Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery, leading over 80 staff. From 1985-2007 at GSK Douglas and staff identified more than 25 compounds selected for development, with 1 Approved, 1 NDA filed and 1 compound completing Phase III clinical trials. In 2007 Douglas joined Galleon Pharmaceuticals, a start-up company in Horsham, PA, as Senior Vice President, Drug Discovery, where in less than 6 months he built a high-quality team working on medicines for ventilator control conditions, such as sleep apnea. Douglas is recognized internationally as an expert in the area of respiratory science and therapeutics. He is author of over 100 peer-reviewed papers, more than 40 book chapters and reviews, and co-edited 2 books. Douglas is currently President of Hay Drug Discovery Consulting, LLC, which he formed in September, 2009.

This site is registered on as a development site.